John "Lippy" Lippincott
About John "Lippy" Lippincott
John 'Lippy' Lippincott serves as the Senior Vice President of Therapeutic Discovery Strategies at Alloy Therapeutics, Inc. He has extensive experience in therapeutic discovery, having held various roles at companies such as Pfizer, Ablexis, and AlivaMab Discovery Services.
Current Role at Alloy Therapeutics
John Lippincott serves as the Senior Vice President of Therapeutic Discovery Strategies at Alloy Therapeutics, Inc. since 2023. In this role, he focuses on advancing therapeutic discovery initiatives and strategies within the organization. His position is based in San Diego, where he utilizes his extensive background in research and development to drive innovation in therapeutic discovery.
Previous Experience at Ablexis, LLC
Lippincott worked at Ablexis, LLC in various capacities from 2012 to 2021. He initially served as the Director of Research Operations from 2012 to 2015, where he managed research activities. Following this, he worked as a Consultant from 2015 to 2021. His tenure at Ablexis contributed to his expertise in therapeutic discovery and operational management.
Educational Background
John Lippincott earned his Ph.D. in Cell Biology from Harvard Medical School, where he studied from 1996 to 2000. Prior to this, he completed his undergraduate studies at the University of Washington, obtaining a Bachelor of Science in Microbiology and Biochemistry from 1993 to 1996. His educational background laid the foundation for his career in therapeutic discovery.
Career at Pfizer
Lippincott spent nine years at Pfizer, where he held the position of Senior Principal Scientist from 2001 to 2010. During his time there, he led the hybridoma group at the San Diego site, focusing on therapeutic discovery projects. His work at Pfizer involved both internal and co-development efforts in the field of therapeutic discovery.
Leadership at AlivaMab Discovery Services
At AlivaMab Discovery Services, Lippincott held multiple roles, including Vice President of Research from 2018 to 2022 and Senior Vice President of Therapeutic Discovery Strategies from 2022 to 2023. He built and led teams that provided therapeutic antibody discovery services, enhancing the company's capabilities in the field. His leadership contributed to the growth and success of the organization.